Published in Radiology on August 24, 2011
Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results. Eur Radiol (2015) 0.83
Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know? Eur Radiol (2012) 0.79
PREDICT: model for prediction of survival in localized prostate cancer. World J Urol (2015) 0.75
Re: Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume. J Urol (2012) 0.75
MRI in prostate cancer. Iran Red Crescent Med J (2013) 0.75
An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review. Radiat Oncol (2017) 0.75
Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy. Adv Radiat Oncol (2016) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Multiple imputation: a primer. Stat Methods Med Res (1999) 17.79
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol (2008) 4.11
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology (2005) 2.49
Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol (1999) 2.48
Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med (2000) 2.45
Serial biopsy results in prostate cancer screening study. J Urol (2002) 2.30
PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2004) 2.18
The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer (2008) 1.98
Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol (2000) 1.80
Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol (2001) 1.79
Prostate specific antigen only progression of prostate cancer. J Urol (2000) 1.77
Prostate cancer nomograms: an update. Eur Urol (2006) 1.71
Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med (2001) 1.70
Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology (2004) 1.58
Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol (2005) 1.42
Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology (2005) 1.30
Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology (2006) 1.24
Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol (2000) 1.20
Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol (1997) 1.20
Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer (1999) 1.16
Improved solvent suppression and increased spatial excitation bandwidths for three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-echo pulses. J Magn Reson Imaging (1997) 1.16
Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology (2006) 1.14
Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology (2002) 1.14
The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer (1999) 1.09
Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging (2007) 1.08
Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed (2009) 1.05
Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.05
Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology (2007) 1.04
Prostate tissue and serum markers. Adv Clin Path (2000) 1.01
Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience. Radiology (2008) 0.99
MR imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am (2006) 0.98
Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol Med (2005) 0.94
Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU Int (2009) 0.93
MR imaging and MR spectroscopic imaging of prostate cancer. Magn Reson Imaging Clin N Am (2004) 0.92
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys (2010) 0.90
3D MR spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol (2007) 0.87
Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 0.85
Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA <or=10, and clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2003) 0.83
Correlation between prostate needle biopsy and radical prostatectomy Gleason gradings of 111 cases with prostatic adenocarcinoma. Urol J (2004) 0.81
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys (2007) 0.80
3-D computer visualization and interactive prostate biopsy simulation leads to an improved systematic technique for the detection of prostate cancer: clinical correlation. Stud Health Technol Inform (2000) 0.78
Diagnosis and localization of prostate carcinoma by fine-needle aspiration cytology and correlation with histologic whole-organ sections after radical prostatectomy. Am J Clin Pathol (1990) 0.77
Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 8.71
The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr (2013) 6.18
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res (2008) 4.79
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med (2013) 4.23
Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med (2007) 4.13
Performance benchmarks for diagnostic mammography. Radiology (2005) 3.40
Double spin-echo sequence for rapid spectroscopic imaging of hyperpolarized 13C. J Magn Reson (2007) 3.35
Factors associated with mammography utilization: a systematic quantitative review of the literature. J Womens Health (Larchmt) (2008) 3.02
Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst (2007) 2.75
Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology (2007) 2.48
Compressed sensing for resolution enhancement of hyperpolarized 13C flyback 3D-MRSI. J Magn Reson (2008) 2.39
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35
Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer (2008) 2.23
Evaluation of abnormal mammography results and palpable breast abnormalities. Ann Intern Med (2003) 2.20
Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice. J Magn Reson (2009) 2.05
13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab (2011) 2.05
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Imaging of retained surgical sponges in the abdomen and pelvis. AJR Am J Roentgenol (2003) 2.02
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol (2010) 1.97
Radiologist characteristics associated with interpretive performance of diagnostic mammography. J Natl Cancer Inst (2007) 1.95
Mammographic breast density and family history of breast cancer. J Natl Cancer Inst (2003) 1.95
3D compressed sensing for highly accelerated hyperpolarized (13)C MRSI with in vivo applications to transgenic mouse models of cancer. Magn Reson Med (2010) 1.92
Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med (2003) 1.89
Effect of a clinical practice improvement intervention on Chlamydial screening among adolescent girls. JAMA (2002) 1.85
Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. J Magn Reson (2010) 1.84
Characterization of cystic pancreatic masses: relative accuracy of CT and MRI. AJR Am J Roentgenol (2007) 1.83
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res (2010) 1.81
Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.78
Distinguishing features of self-limiting adult small-bowel intussusception identified at CT. Radiology (2003) 1.76
Breast cancer yield for screening mammographic examinations with recommendation for short-interval follow-up. Radiology (2005) 1.75
Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol (2008) 1.73
Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology (2004) 1.69
Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med (2008) 1.69
Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology (2002) 1.68
Fast dynamic 3D MR spectroscopic imaging with compressed sensing and multiband excitation pulses for hyperpolarized 13C studies. Magn Reson Med (2010) 1.67
Investigation of tumor hyperpolarized [1-13C]-pyruvate dynamics using time-resolved multiband RF excitation echo-planar MRSI. Magn Reson Med (2010) 1.64
Feasibility of using hyperpolarized [1-13C]lactate as a substrate for in vivo metabolic 13C MRSI studies. Magn Reson Imaging (2008) 1.64
Pulse sequence for dynamic volumetric imaging of hyperpolarized metabolic products. J Magn Reson (2008) 1.64
Multiband excitation pulses for hyperpolarized 13C dynamic chemical-shift imaging. J Magn Reson (2008) 1.62
Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology (2007) 1.61
In vivo carbon-13 dynamic MRS and MRSI of normal and fasted rat liver with hyperpolarized 13C-pyruvate. Mol Imaging Biol (2009) 1.61
Monitoring urea transport in rat kidney in vivo using hyperpolarized ¹³C magnetic resonance imaging. Am J Physiol Renal Physiol (2012) 1.60
Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol (2008) 1.60
Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology (2004) 1.58
Screening for asymptomatic Chlamydia infections among sexually active adolescent girls during pediatric urgent care. Arch Pediatr Adolesc Med (2009) 1.56
A novel application of 1H magnetic resonance spectroscopy: non-invasive identification of spermatogenesis in men with non-obstructive azoospermia. Hum Reprod (2010) 1.56
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer (2004) 1.55
Radiologic mimics of cirrhosis. AJR Am J Roentgenol (2010) 1.53
Screening mammography in the American elderly. Am J Prev Med (2006) 1.52
Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. Proc Natl Acad Sci U S A (2011) 1.52
Use of CT cholangiography to evaluate the biliary tract after liver transplantation: initial experience. Liver Transpl (2004) 1.50
Short-interval follow-up mammography: are we doing the right thing? J Natl Cancer Inst (2003) 1.49
Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience. Radiology (2005) 1.48
Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology (2009) 1.48
Airport full-body screening: what is the risk? Arch Intern Med (2011) 1.45
Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: insights from the NCDR(®). Catheter Cardiovasc Interv (2013) 1.43
Evidence-based target recall rates for screening mammography. Radiology (2007) 1.39
Myocardial perfusion scans: projected population cancer risks from current levels of use in the United States. Circulation (2010) 1.38
Measurement of breast density with dual X-ray absorptiometry: feasibility. Radiology (2002) 1.38
Hyperpolarized [2-13C]-fructose: a hemiketal DNP substrate for in vivo metabolic imaging. J Am Chem Soc (2009) 1.38
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Distinguishing screening from diagnostic mammograms using Medicare claims data. Med Care (2014) 1.37
Differences in the quality of breast cancer care among vulnerable populations. Cancer (2005) 1.36
Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology (2004) 1.36
Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging (2008) 1.35
Metabolic imaging in the anesthetized rat brain using hyperpolarized [1-13C] pyruvate and [1-13C] ethyl pyruvate. Magn Reson Med (2010) 1.34
Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology (2007) 1.32
Prediction of random effects in linear and generalized linear models under model misspecification. Biometrics (2011) 1.32
Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem (2003) 1.31
Registration of MR prostate images with biomechanical modeling and nonlinear parameter estimation. Med Phys (2006) 1.30
Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology (2007) 1.29
Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology (2005) 1.27
Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med (2008) 1.25
CT signs of hepatofugal portal venous flow in patients with cirrhosis. AJR Am J Roentgenol (2003) 1.24
Accuracy of plain abdominal radiographs in the detection of retained surgical needles in the peritoneal cavity. Ann Surg (2008) 1.24
Imaging of blood flow using hyperpolarized [(13)C]urea in preclinical cancer models. J Magn Reson Imaging (2011) 1.23
Analysis of hyperpolarized dynamic 13C lactate imaging in a transgenic mouse model of prostate cancer. Magn Reson Imaging (2009) 1.21
Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging (2008) 1.21
Multi-kernel graph embedding for detection, Gleason grading of prostate cancer via MRI/MRS. Med Image Anal (2012) 1.20
Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys (2004) 1.19
The association of blood pressure and mortality differs by self-reported walking speed in older Latinos. J Gerontol A Biol Sci Med Sci (2012) 1.19
Fetal tracheolaryngeal airway obstruction: prenatal evaluation by sonography and MRI. Pediatr Radiol (2010) 1.19
Imaging of nontraumatic adrenal hemorrhage. AJR Am J Roentgenol (2012) 1.18
Hyperpolarized (13)C spectroscopy and an NMR-compatible bioreactor system for the investigation of real-time cellular metabolism. Magn Reson Med (2010) 1.18
Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol (2003) 1.18
Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology (2010) 1.18
Evaluation of the ERETIC method as an improved quantitative reference for 1H HR-MAS spectroscopy of prostate tissue. Magn Reson Med (2009) 1.18
Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology (2010) 1.18
Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. AJR Am J Roentgenol (2004) 1.17
Accuracy of mammographic breast density analysis: results of formal operator training. Cancer Epidemiol Biomarkers Prev (2002) 1.17
Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med (2005) 1.17